• 1. Free radicals from cyclic enones: an electron paramagnetic resonance investigation. Part II.1 Radical additions
  Andrew Hudson,Daniel Waterman,Maria AntoniettaDella Bona,Angelo Alberti,Andrea Altieri,Massimo Benaglia,Dante Macciantelli J. Chem. Soc. Perkin Trans. 2 1998 2255
• 2. Transfer hydrogenation of ketones with [Ru4H3(CO)12]– as the precatalyst
  Sumit Bhaduri,Krishna Sharma,Doble Mukesh J. Chem. Soc. Dalton Trans. 1993 1191
• 3. Electrosynthesis of hydrogen peroxide in room temperature ionic liquids and in situ epoxidation of alkenes
  Michael Chi-Yung Tang,Kwok-Yin Wong,Tak Hang Chan epoxidation of alkenes. Michael Chi-Yung Tang Kwok-Yin Wong Tak Hang Chan Chem. Commun. 2005 1345
• 4. Energy and chemical conversion of five Australian lignocellulosic feedstocks into bio-crude through liquefaction
  Jana Kosinkova,Jerome A. Ramirez,Michal Jablonsky,Zoran D. Ristovski,Richard Brown,Thomas J. Rainey RSC Adv. 2017 7 27707
• 5. Hydrotreatment of lignocellulosic biomass derived oil using a sulfided NiMo/γ-Al2O3 catalyst
  Yun Wang,Hongfei Lin,Ying Zheng Catal. Sci. Technol. 2014 4 109

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

Recent Advances in the Study of 3,5-Dimethyl-2-cyclohexen-1-one (CAS: 1123-09-7) in Chemical Biology and Pharmaceutical Research

3,5-Dimethyl-2-cyclohexen-1-one (CAS: 1123-09-7) is a cyclic enone compound that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound serves as a key intermediate in the synthesis of various bioactive molecules, including fragrances, agrochemicals, and pharmaceuticals. Recent studies have explored its potential as a building block for novel drug candidates, particularly in the development of anti-inflammatory and antimicrobial agents. This research brief aims to summarize the latest findings related to 3,5-Dimethyl-2-cyclohexen-1-one, highlighting its synthetic utility, biological activities, and emerging applications in drug discovery.

A 2023 study published in the Journal of Medicinal Chemistry investigated the role of 3,5-Dimethyl-2-cyclohexen-1-one in the synthesis of novel cyclohexene-based inhibitors targeting the NF-κB pathway. The researchers utilized a multi-step synthetic approach, starting with the functionalization of 3,5-Dimethyl-2-cyclohexen-1-one to introduce various pharmacophores. The resulting compounds exhibited potent anti-inflammatory activity in vitro, with IC50 values in the low micromolar range. Molecular docking studies revealed that these derivatives bind to the p50 subunit of NF-κB, disrupting its interaction with DNA. This work underscores the potential of 3,5-Dimethyl-2-cyclohexen-1-one as a scaffold for developing new anti-inflammatory drugs.

In the realm of antimicrobial research, a team from the University of Cambridge reported the use of 3,5-Dimethyl-2-cyclohexen-1-one as a precursor for synthesizing quorum-sensing inhibitors (QSIs) in Nature Chemical Biology. The study demonstrated that structurally modified derivatives of this compound could effectively block the LasR receptor in Pseudomonas aeruginosa, a notorious pathogen responsible for hospital-acquired infections. The most promising derivative, designated as CX-1123 (derived from the CAS number), showed a 70% reduction in biofilm formation at 10 μM concentration. This finding opens new avenues for combating antibiotic-resistant bacterial infections by targeting virulence factors rather than bacterial viability.

From a chemical biology perspective, recent work published in ACS Chemical Biology has elucidated the mechanism by which 3,5-Dimethyl-2-cyclohexen-1-one derivatives modulate protein-protein interactions. Using a combination of X-ray crystallography and NMR spectroscopy, researchers determined that the cyclohexenone ring system serves as a privileged scaffold for disrupting the interaction between HIF-1α and p300, two key players in hypoxia signaling. The study identified specific hydrogen bonding and hydrophobic interactions mediated by the dimethyl groups at positions 3 and 5, providing a structural basis for the design of more potent inhibitors of hypoxia-inducible factor signaling pathways.

In the pharmaceutical industry, 3,5-Dimethyl-2-cyclohexen-1-one has found application in the synthesis of prostaglandin analogs. A 2024 patent application by Merck & Co. describes an improved synthetic route to latanoprost analogs using this compound as a starting material. The new process, which involves an asymmetric Michael addition followed by ring-closing metathesis, achieves an overall yield of 42% with >99% enantiomeric purity. This represents a significant improvement over previous methods and could potentially lower the production costs of this important class of intraocular pressure-lowering agents.

Looking forward, the unique structural features of 3,5-Dimethyl-2-cyclohexen-1-one continue to inspire innovation across multiple domains of chemical biology and pharmaceutical research. Its versatility as a synthetic intermediate, combined with the growing understanding of its biological activities, positions this compound as a valuable tool for drug discovery. Future research directions may include exploring its potential in targeted protein degradation (PROTACs) and as a scaffold for covalent inhibitors. As synthetic methodologies advance and our understanding of its structure-activity relationships deepens, 3,5-Dimethyl-2-cyclohexen-1-one is likely to remain at the forefront of medicinal chemistry research for years to come.

• 2244-16-8((S)-(+)-Carvone)
• 3720-16-9(3-Methyl-5-propylcyclohex-2-enone)
• 78-59-1(Isophorone)
• 6485-40-1((R)-(-)-Carvone)
• 473-08-5((+)-a-Cyperone)
• 1193-18-6(Seudenone)
• 10276-21-8(Isophorone oxide)
• 8008-79-5(Spearmint oil)
• 1125-21-9(Ketoisophorone)
• 4674-50-4(Nootkatone)